Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: An analysis from the gvhd working group of the Japan society for hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 8, 2013, Pages 1183-1189

  Murata, Makoto ^a,b   Nakasone, Hideki ^b,c   Kanda, Junya ^b,c   Nakane, Takahiko ^c,d   Furukawa, Tatsuo ^b,e   Fukuda, Takahiro ^f   Mori, Takehiko ^g   Taniguchi, Shuichi ^h   Eto, Tetsuya ⁱ   Ohashi, Kazuteru ^j   Hino, Masayuki ^d   Inoue, Masami ^k   Ogawa, Hiroyasu ^l   Atsuta, Yoshiko ^a   Nagamura Inoue, Tokiko ^m   Yabe, Hiromasa ⁿ   Morishima, Yasuo ^o   Sakamaki, Hisashi ^j   Suzuki, Ritsuro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ HAMANOMACHI HOSPITAL   (Japan)

^j TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^k RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^l HYOGO COLLEGE OF MEDICINE   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Acute graft versus host disease; Cord blood transplantation; Corticosteroid

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BONE MARROW; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; RETROSPECTIVE STUDY; T CELL DEPLETION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD;

ACUTE GRAFT-VERSUS-HOST DISEASE; CORD BLOOD TRANSPLANTATION; CORTICOSTEROID;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; JAPAN; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84880441178     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.05.003     Document Type: Article

References (34)

1. Cahn J.Y., Bordigoni P., Tiberghien P., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995, 60:939-942.
2. Cragg L., Blazar B.R., Defor T., et al. Arandomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
3. Graziani F., Van Lint M.T., Dominietto A., et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002, 87:973-978.
4. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial. Blood 2004, 104:1559-1564.
5. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
6. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
7. Couriel D.R., Saliba R., de Lima M., et al. Aphase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:1555-1562.
8. Martin P.J., Rizzo J.D., Wingard J.R., et al. First- and second-line systemic treatment of acute graft-versus-host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
9. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
10. Martin P.J., Schoch G., Fisher L., et al. Aretrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990, 76:1464-1472.
11. Weisdorf D.J., Snover D.C., Haake R., et al. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 1990, 76:624-629.
12. Roy J., McGlave P.B., Filipovich A.H., et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy. Bone Marrow Transplant 1992, 10:77-82.
13. Hings I.M., Severson R., Filipovich A.H., et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994, 58:437-442.
14. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
15. Lee K.H., Choi S.J., Lee J.H., et al. Prognostic factors identifiable at the timeof onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005, 90:939-948.
16. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
17. Atsuta Y., Suzuki R., Yoshimi A., et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007, 86:269-274.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009, 15:367-369.
20. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999, 18:695-706.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
22. Cox D.R. Regression models and life tables. JRoyal Stat Soc [B] 1972, 34:187-220.
23. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
24. Rocha V., Labopin M., Sanz G., et al. Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. NEngl J Med 2004, 351:2276-2285. Acute Leukemia Working Party of European Blood and Marrow Transplant Group.
25. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004, 104:3813-3820.
26. Barker J.N., Hough R.E., van Burik J.A., et al. Serious infections after unrelated donor transplantation in 136 children: Impact of stem cell source. Biol Blood Marrow Transplant 2005, 11:362-370.
27. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. Lancet 2007, 369:1947-1954.
28. Atsuta Y., Suzuki R., Nagamura-Inoue T., et al. Japan Cord Blood Bank Network. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009, 113:1631-1638.
29. Eapen M., Rocha V., Sanz G., et al. National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol 2010, 11:653-660. Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation).
30. Morishima Y., Morishita Y., Tanimoto M., et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989, 74:2252-2256.
31. Morishima Y., Kodera Y., Hirabayashi N., et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995, 15:235-239.
32. Van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998, 92:2288-2293.
33. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
34. Ruutu T., Hermans J., van Biezen A., et al. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 22:614-615.